

**PET and aortic aneurysm:** Rudd and colleagues provide an overview of PET in aortic aneurysm, with a focus on the ability of imaging to predict expansion, and preview a related article in this issue of *JNM*. . . . . **Page 971**

**Calcium in noncalcified lesions:** Strauss and Narula look at the pathophysiology of atherosclerosis, the clinical significance of intimal arterial calcification, and an article in this issue of *JNM* on serial  $^{18}\text{F}$ -NaF vascular imaging in this setting. . . . . **Page 974**

**Retention of  $^{177}\text{Lu}/^{177\text{m}}\text{Lu}$ -DOTATATE:** Sjögreen Gleisner and colleagues investigate long-term activity retention of radionuclides from peptide receptor therapy dosimetry and discuss the implications for timing of post-dosimetry imaging. . . . . **Page 976**

**Quantifying SPECT uptake:** Rowe and colleagues report on the variability of normal abdominal organ uptake values in serial  $^{111}\text{In}$ -pentetreotide SPECT studies in patients with neuroendocrine or carcinoid tumors. . . . . **Page 985**

**PET/CT follow-up in colorectal cancer:** Marcus and colleagues explore the added value of a fourth and subsequent follow-up PET/CT scans in clinical assessment and patient management after primary treatment for colorectal cancer. . . . . **Page 989**

**PET vs. PET/CT in esophageal cancer:** Goense and colleagues provide a metaanalysis of the performance of  $^{18}\text{F}$ -FDG PET and integrated  $^{18}\text{F}$ -FDG PET/CT in diagnosing recurrent esophageal cancer after initial treatment with curative intent. . . . . **Page 995**

**$^{18}\text{F}$ -DCFBC PET in primary prostate cancer:** Rowe and colleagues evaluate PET imaging with this prostate-specific membrane antigen–targeting tracer in men undergoing definitive surgery and correlate results with those from pelvic MR imaging and pathology. . . . . **Page 1003**

**Mortality prediction in heart failure:** Narula and colleagues apply multiple multivariate risk modeling techniques to determine the independent prognostic ability of  $^{123}\text{I}$ -MIBG imaging for mortality outcomes in individuals with heart failure. . . . . **Page 1011**

**NaF uptake in atherosclerotic plaque:** Fiz and colleagues use PET/CT to look at vascular  $^{18}\text{F}$ -NaF uptake in plaque of 3 different densities and discuss possibilities for molecular

assessment of calcium deposition in early stages of plaque formation. . . . . **Page 1019**

**Therapy control in graft infections:** Husmann and colleagues report on the clinical value of  $^{18}\text{F}$ -FDG PET/CT for therapy control and management in patients with prosthetic vascular graft infections. . . . . **Page 1024**

**PET/CT in AAA:** Morel and colleagues describe the results of an analysis of serial  $^{18}\text{F}$ -FDG PET imaging of rates of growth in medically treated abdominal aortic aneurysms and of metabolic parameters of associated parietal inflammation. . . . . **Page 1030**

**Midbrain function in PD:** Joutsa and colleagues use  $^{123}\text{I}$ -FP-CIT SPECT to elucidate midbrain dopaminergic projections and extrastriatal serotonergic abnormalities in patients with Parkinson disease. . . . . **Page 1036**

**Voxelwise parameter correlations and A $\beta$  load:** Sojkova and colleagues use  $^{15}\text{O}$ -H $_2$ O and  $^{11}\text{C}$ -PiB PET to research local relationships between distribution volume ratio, cerebral blood flow, and amyloid- $\beta$  load in nondemented older adults. . . . . **Page 1042**

**Quantifying inflammation in neurodegeneration:** Lavisse and colleagues assess  $^{18}\text{F}$ -DPA-714 PET in healthy translocator protein–genotyped volunteers and explore a method designed to eliminate the need for invasive arterial blood sampling. . . . . **Page 1048**

**Enhancing T cell imaging sensitivity:** Moroz and colleagues focus on human reporter gene systems and the minimum numbers of T cells that can be visualized with different nuclear reporter systems and PET or SPECT imaging. . . . . **Page 1055**

**MR AC in PET/MR:** Paulus and colleagues detail a novel model-based attenuation correction method that improves PET quantification of bone and nearby soft tissue in whole-body hybrid PET/MR imaging. . . . . **Page 1061**

**Pediatric PET/MR AC:** Bezrukov and colleagues assess the impact of 2 potentially influential factors—inter- and inpatient variability of attenuation coefficients and anatomic variability—in PET/MR imaging in children. . . . . **Page 1067**

**GLP-1 receptor PET/CT:** Antwi and colleagues determine whether PET/CT imaging

with a novel  $^{68}\text{Ga}$ -labeled glucagonlike peptide-1 receptor–targeting agent is feasible and sensitive in detecting benign insulinomas and compare results with those from  $^{111}\text{In}$ -DOTA-exendin-4 SPECT/CT. . . . . **Page 1075**

**Current developments in radioembolization:** Braat and colleagues provide an educational overview of indications and approaches in radioembolization, with a focus on patient selection, recent developments, and future applications. . . . . **Page 1079**

**$^{64}\text{Cu}$ -FBP8 and DVT-PE imaging:** Blasi and colleagues explore the feasibility of  $^{64}\text{Cu}$ -FBP8 PET for detecting source thrombi and culprit emboli after deep vein thrombosis and pulmonary embolism and offer human dosimetry estimations. . . . . **Page 1088**

**Anti-PSMA Nanobody:** Chatalic and colleagues describe the development of initial studies with a novel anti–prostate-specific membrane antigen Nanobody for targeted SPECT/CT imaging and therapy of prostate cancer. . . . . **Page 1094**

**Kit-producible  $^{18}\text{F}$ -SiFAlin:** Niedermoser and colleagues research the in vivo properties of good manufacturing practice–compliant and “kitlike producible”  $^{18}\text{F}$ -SiFA– and  $^{18}\text{F}$ -SiFAlin–modified TATE derivatives for PET imaging in somatostatin receptor–bearing tumors. . . . . **Page 1100**

**Liposomal therapy and  $^{18}\text{F}$ -FDG PET:** Hwang and colleagues assess delivery of angiogenic peptides with vascular endothelial growth factor in cerebral ischemia and explore the potential of  $^{18}\text{F}$ -FDG PET imaging in an animal model of ischemic stroke treatment. . . . . **Page 1106**

**Monitoring oncogene expression:** Mendler and colleagues report on a comparison of  $^{89}\text{Zr}$  and  $^{124}\text{I}$  in labeling of the recombinant  $\alpha\text{HER2}$  Fab-PAS $_{200}$  protein tracer for immuno-PET imaging of HER2-positive human xenograft tumors in mice. . . . . **Page 1112**

**Targeted radionuclide therapy workshop:** Fahey and colleagues summarize the proceedings of a second joint SNMMI/National Cancer Institute expert meeting on current developments and future potential for targeted radionuclide therapy, held in October 2014. . . . . **Page 1119**